EyePoint Pharmaceuticals所有资讯

JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价45美元

moomoo资讯01/02 11:32 (美东)

H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价22美元

moomoo资讯2024/12/05 12:31 (美东)

JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价45美元

moomoo资讯2024/12/05 11:33 (美东)

eyepoint pharmaceuticals的目标股价维持在每股22.00美元，HC Wainwright & Co.继续保持。

道琼斯2024/12/05 06:30 (美东)

eyepoint pharmaceuticals 分析师评级

Benzinga2024/12/05 06:20 (美东)

JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价45美元

moomoo资讯2024/12/02 17:31 (美东)

贝雅维持EyePoint Pharmaceuticals(EYPT.US)买入评级，下调目标价至33美元

moomoo资讯2024/11/11 07:31 (美东)

JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价45美元

moomoo资讯2024/11/11 07:31 (美东)

H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级，下调目标价至22美元

moomoo资讯2024/11/11 07:31 (美东)

eyepoint pharmaceuticals被HC Wainwright & Co买入维持

道琼斯2024/11/11 07:24 (美东)

eyepoint pharmaceuticals价格目标从30.00美元降至22.00美元，由HC Wainwright & Co.进行裁减。

道琼斯2024/11/11 07:24 (美东)

TD Cowen维持EyePoint Pharmaceuticals(EYPT.US)买入评级，下调目标价至20美元

moomoo资讯2024/11/07 12:30 (美东)

eyepoint pharmaceuticals：临床试验进展及有望的中期数据推动了买入评级

TipRanks2024/11/07 11:50 (美东)

丰业银行维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价18美元

moomoo资讯2024/10/29 07:34 (美东)

eyepoint pharmaceuticals被Chardan Capital维持为买入

道琼斯2024/10/29 07:11 (美东)

eyepoint pharmaceuticals 分析师评级

Benzinga2024/10/29 06:59 (美东)

第一资本维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价35美元

moomoo资讯2024/10/28 11:32 (美东)

JonesTrading首予EyePoint Pharmaceuticals(EYPT.US)买入评级，目标价45美元

moomoo资讯2024/10/28 10:32 (美东)

贝雅维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价38美元

moomoo资讯2024/10/25 11:34 (美东)

H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价30美元

moomoo资讯2024/10/25 06:31 (美东)